The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).
 
Charlene Mantia
Consulting or Advisory Role - AADi; Nextech; Synthekine
Research Funding - Bristol-Myers Squibb (Inst)
 
Opeyemi Jegede
Research Funding - Bristol Myers Squibb Foundation
 
Hollis Viray
No Relationships to Disclose
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Agenus; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; GlaxoSmithKline; Idera; Merck; Novartis; Oncorena; PACT Pharma; Pfizer; Pliant; Pyxis; Sanofi; Scholar Rock; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Lisa Rosenblatt
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Amgen Astellas BioPharma (I); Bristol Myers Squibb; Merck (I)
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Xin Yin
Employment - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Cullinan Oncology; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Synthekine; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
 
Meredith M. Regan
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Tersera; Tolmar
Research Funding - AstraZeneca (Inst); Bayer (Inst); bioTheranostics (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); TerSera (Inst)